Alivus Life Sciences Ltd (ALIVUS) Stock Price & News

ALIVUS:NSE

Alivus Life Sciences Ltd

₹1,353.00

+0.56%

(+7.50) 1D

Sep 29, 3:30:00 PM GMT+5:30 · INR

All symbols

YTD

MAX

	Symbol	Price	Change	% Change

Last report

Jul 31, 2026

Fiscal period

Q1 2027

EPS / Est. (INR)

₹13.01 / ₹12.10

+7.52%beat

Revenue / Est. (INR)

6.40B / 6.68B

-4.06%miss

Fiscal Q1 2027 earnings call

Waiting for the earnings call

At a glance

Insights from the latest news and reports

Previous reportsAll values in INR

Loading Previous Earnings...

All values in INR	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	5.88B	6.73B	6.89B	6.40B
Cost of goods sold	2.49B	2.76B	3.45B	2.55B
Cost of revenue	2.49B	2.76B	3.45B	2.55B
Research and development expenses	-	-	-	-
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	664.00M	663.70M	965.39M	682.45M
Operating expense	1.78B	1.85B	1.49B	1.94B
Total operating expenses	4.27B	4.61B	4.94B	4.49B
Operating income	1.61B	2.12B	1.95B	1.91B
Other non operating income	147.20M	139.28M	-368.69M	224.01M
EBT including unusual items	1.74B	1.98B	2.16B	2.12B
EBT excluding unusual items	1.74B	2.24B	1.78B	2.12B
Income tax expense	441.11M	481.31M	531.38M	521.47M
Effective tax rate	25.33%	24.26%	24.62%	24.57%
Other operating expenses	934.91M	988.28M	325.80M	1.05B
Net income	1.30B	1.50B	1.63B	1.60B
Net profit margin	22.11%	22.33%	23.60%	25.00%
Earnings per share	10.58	13.80	13.22	13.01
Interest and investment income	-	-	9.66M	-
Interest expense	-13.18M	-14.94M	-13.09M	-13.07M
Net interest expenses	-13.18M	-14.94M	-3.43M	-13.07M
Depreciation and amortization charges	184.35M	196.58M	202.00M	205.85M
EBITDA	1.78B	2.25B	2.11B	2.10B
Gain or loss from assets sale	-	-	-	-

Finance